Fig. 4

Ru1 halts PDAC growth and relapse in vivo. A Fold change in pancreas weight ± SEM in mice injected orthotopically with Panc265 cells determined at treatment cessation (n=4-5 mice/group). *p < 0.05, ** p<0.01, ns = not significant, as determined by one-way ANOVA with Dunnett post-test, compared to Ctl. B Representative photos of Panc265 orthotopic tumors extracted from mice 3 weeks post treatment initiation. C Mean percentage of EpCAM+/CXCR4+/CD90+ PaCSCs ± SD, determined by flow cytometry, in extracted tumors from (A). *p < 0.05, *** p<0.001, ns = not significant, as determined by one-way ANOVA with Dunnett post-test, compared to Ctl. D Average fold change in tumor volume ± SEM in mice bearing Panc185 PDXs and treated with diluent control (Ctl), Ru1 (1.4mg/kg r.o.; daily), Gemcitabine (50mg/kg; twice per week) or a combination of both and compared to d0 (n=6-12 tumors/group). E Fold change in Panc185 tumor volumes ± SEM determined at treatment cessation and at the indicated time during relapse. *p < 0.05; **** p<0.0001, as determined by unpaired two-sided Student’s t-test or a one-way ANOVA with Dunnett post-test, compared to Ctl. F Average fold change in tumor volume ± SEM in mice bearing PancA6L PDXs and treated with diluent control (Ctl), Ru1 (1.4mg/kg r.o.; daily), Gemcitabine (50mg/kg; twice per week) or a combination of both and compared to d0 (n=6-12 tumors/group). G Fold change in PancA6L tumor volumes ± SEM determined at treatment cessation and at the indicated time during relapse. *p < 0.05; **** p <0.0001, as determined by unpaired two-sided Student’s t-test or a one-way ANOVA with Dunnett post-test, compared to Ctl